Published on April 5, 2016

Presently pharmaceutical exports to the US are growing due to the increasing demand for high quality generic drugs in the market. However, the growth rate for exports of pharmaceutical products from India to the US is declining, due to increasing US Food and Drug Administration (FDA) scrutiny on the quality of Pharma products coming from drug manufacturing plants located in India.

Market players said that, in order to boost the growth rate of exports to the US, Indian companies will need to leverage their compliance to US FDA regulations. Currently Indian pharma companies are working constantly on a time-bound action plan with the US FDA. So that in the next two to three years, the results of the effort being put in by the major companies will start showing.

Indian pharmaceutical industry is expected to touch USD 55 billion by 2020. With the efforts of Indian companies Pharma industry will achieve remarkable growth, said by market players.